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Abstract. Oligoribonucleotide conjugates carrying nuclear localization peptide 
sequences at the 3’-end were prepared stepwise on a single support. The siRNA duplex 
carrying the nuclear localization peptide sequence at the 3’-end of the passenger strand 
has similar inhibitory properties as those of unmodified or cholesterol-modified RNA 
duplexes. 
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INTRODUCTION 
 
In the last two decades new compounds comprising small synthetic nucleic acids have 
shown promising results as potential drugs [1, 2]. In these cases, nucleic acids are used 
to inhibit a specific gene by blocking translation or transcription or by stimulating the 
degradation of a particular messenger RNA. Several strategies can be followed. In the 
antisense strategy, synthetic oligonucleotides complementary to the messenger RNA of 
a given gene are used to inhibit the translation of messenger RNA to protein [3, 4]. In 
the siRNA strategy, small RNA duplexes complementary to messenger RNA bind to a 
protein complex named RISC. The complex formed by the antisense or guide RNA 
strand and RISC catalyzes the efficient degradation of a specific messenger RNA, 
thereby lowering the amount of target protein [5, 6].  
Some of the problems encountered during the development of nucleic acids as drugs 
entail the degradation of these by exonucleases under physiological conditions and their 
low uptake by cells. Most of the improvements in the design of nucleic acid derivatives 
aim to enhance stability to nuclease and improve cell uptake without affecting the 
hybridisation properties, which are vital for the efficient inhibitory properties of 
oligonucleotides. A large number of nucleic acid derivatives have been developed [5, 
7]. The conjugation of lipids to oligonucleotides, such as cholesterol [8, 9], produces 
molecules with improved inhibitory properties [10, 11]. 
Oligonucleotide-peptide conjugates are chimeras of oligonucleotides and peptides which 
are produced to add some of the biological or biophysical properties of peptides to 
oligonucleotides. Reaction of oligonucleotides to polylysine [12], basic [13, 14], 
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fusogenic [15, 16] and signal peptides [17, 18] has showed to produce new compounds 
with improved cellular uptake.  
Peptide-oligodeoxynucleotide conjugates are prepared through distinct conjugation 
chemistries, which include either stable or cleavable linkages. In the post-synthetic 
conjugation approach, the two moieties are prepared independently on solid-phase and  
thiols and maleimido groups are especifically introduced to link the two molecules [17, 
19]. In the stepwise approach, oligonucleotide-peptide conjugates are prepared by the 
addition of amino acids and nucleobases using solid-phase protocols on the same solid 
support [16, 20, 21, 22]. In this case, the problem to be solved is the incompatibility of 
standard schemes of protection. For example, at the end of the solid-phase peptide 
synthesis a treatment with acid is usually required, which can lead to partial 
depurination of DNA. In the synthesis of oligonucleotide 3'-peptides, this effect can be 
prevented using Boc-protected amino acids with Fm or Fmoc groups for the protection 
of side chains, a base-labile linker and standard phosphoramidites [16, 20, 21].  
In the RNA interference field, cationic cell-penetrating peptides such as TAT-peptide 
and penetratin, facilitate the cell uptake of siRNA [23-28]. A particulary successful 
result was obtained with a peptide derived from the glycoprotein of the rabies virus 
[23]. The incubation of this peptide, which carryies a polyarginine tail with siRNA, 
produced a complex that facilitates the delivery of siRNA to the central nervous system 
[23]. Most of the results obtained to date using peptides and siRNA were either not 
covalently linked to RNA or covalently linked by the post-synthetic conjugation 
method. Solid-phase protocols for the preparation of aminoacyl-tRNA fragments have 
been described [29, 30]; however to our knowledge there are no data on the preparation 
of RNA-peptide conjugates for RNA interference studies using the stepwise approach.   
 4
Here we describe the stepwise synthesis of oligoribonucleotides carrying nuclear 
localization peptide sequences. Tumor necrosis factor (TNF-a) was selected as a target. 
This protein is a major mediator of apoptosis as well as inflammation and immunity. 
Furthermore, TNF-a has been implicated in the pathogenesis of many human diseases 
and consequently the inhibition of this cytokine is of particular relevance. 
 
EXPERIMENTAL SECTION 
 
Abbreviations:  ACN, acetonitrile; AmHex, 6-aminohexylsuccinyl; Boc, t-
butoxycarbonyl; DBU, 1,8-diazabicyclo[5.4.0]undec-7-ene; DCM, dichloromethane; 
DIEA, N,N-diisopropylethylamine; DMF, N,N-dimethylformamide;  DMT, 4, 4’-
dimethoxytrityl; Fm, fluorenylmethyl; Fmoc, fluorenylmethoxycarbonyl; PEG-PS, 
polyethyleneglycol-polystyrene; PyBOP, (benzotriazol-1-
yloxy)trispyrrolidinophosphonium hexafluorophosphate, TBDMS, t-butyldimethylsilyl; 
TEAA, triethylammonium acetate; TFA, trifluoroacetic acid.     
 
Oligonucleotides.  
The following RNA sequences were obtained from commercial sources (Sigma-Proligo, 
Dharmacon): sense or passenger scrambled 5’-CAGUCGCGUUUGCGACUGG-dT-
dT-3’, antisense or guide scrambled 5’-CCAGUCGCAAACGCGACUG-dT-dT-3’, 
antisense or guide anti-TNFa: 5’-GAGGCUGAGACAUAGGCAC-dT-dT-3’ and sense 
or passenger anti-TNFa: 5’-GUGCCUAUGUCUCAGCCUC-dT-dT-3’. RNA 
monomers in capital letters, dT represents 2’-deoxythymidine. The 3’-cholesterol 
passenger anti-TNFa: strand 5’- GUGCCUAUGUCUCAGCCUC-dT-dT-3’-cholesterol 
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was prepared using the cholesterol-tetraethyleneglycol (TEG)-3’-CPG support from 
commercial sources (Glen Research). The anti-TNFa siRNA has been previously 
described to efficiently downregulate murine TNFa mRNA [31]. 
 
Synthesis of oligonucleotide-peptide conjugates. 
Oligonucleotide-peptide conjugates were synthesized by the stepwise approach [32]. 
The following sequences were prepared I) 5'-uggauucgu-3’-p-O-(CH2)5CONH-NAla-
Lys-Lys-Lys-Lys-Leu-Asp-LysC-CONH-(CH2)6-OH; II) 5' CUGAC-dT-ps-dT-3’-ps-O-
(CH2)5CONH-NAla-Lys-Lys-Lys-Lys-Leu-Asp-LysC-CONH-(CH2)6-OH; and III) 5'- 
GUGCCUAUGUCUCAGCCUC-dT-dT-p-O-(CH2)5CONH-NAla-Lys-Lys-Lys-Lys-
Leu-Asp-LysC-CONH-(CH2)6-OH. The following abbreviations are used: 2’-O-methyl-
RNA monomers in low case, RNA monomers in capital letters, dT: 2’-deoxythymidine, 
p: phosphate, ps: phosphorothioate linkages. Guanosine was protected with the 
dimethylaminomethylidene group, cytidine was protected with the acetyl group and 
adenosine with the benzoyl group. The 2’-OH protecting group for the RNA monomers 
was the t-butyldimethylsilyl (TBDMS) group. Boc-aminohexanol was reacted with 
succinic anhydride to form the corresponding hemisuccinate [20], which was reacted 
with amino functionalized PEG-PS support. Peptide chain was elongated manually in 
DMF using a 5-fold excess of amino acid Boc-protected amino acid and a 5-fold excess 
of PyBOP and a 10-fold excess of DIEA for 1 h. Lysine was protected with the Fmoc 
group and aspartic acid was protected with the Fm group. Once the peptide sequence 
was completed, the resulting support was reacted with p-nitrophenyl  6-(4,4'-
dimethoxytrityloxy)hexanoate [20]. The addition of this building block introduces an 
hydroxyl group to the existing peptide. This hydroxyl group is required for the assembly 
of the oligonucleotide. The linker was coupled to the peptide-support using PyBOP and 
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DIEA as described above. The unreacted amino groups of the resulting support were 
blocked with acetic anhydride and DIEA. Oligonucleotides were prepared on a DNA 
synthesizer (Applied Biosystems 3400) using 2-cyanoethyl phosphoramidites. The 
following solutions were used: 0.4 M 1H-tetrazol in ACN (activation); 3% 
trichloroacetic acid in DCM (detritylation), acetic anhydride / pyridine /tetrahydrofurane 
(1: 1: 8) (capping A), 10 % N-methylimidazole in tetrahydrofurane  (capping B), 0.01 M 
iodine in tetrahydrofurane/ pyridine /water (7: 2: 1) (oxidation).  The phosphoramidites 
were dissolved in dry DCM (0.1 M). A modified cycle was used: Coupling time was 
increased to 5 min, capping and oxidation times to 1 min, and detritylation time to 2 
min (4 x 30 s). In the synthesis of the 2’-O-methyl-RNA sequence I, the last DMT-
protecting group was not removed. In the RNA sequences II and III, the last DMT 
group was removed because the DMT is partially lost during the fluoride treatment. The 
average coupling yield was around 97-98% per step for RNA monomers and 99% for 
2’-O-methyl-RNA monomers. The solid supports containing the oligonucleotide-
peptide conjugates were washed with acetonitrile, treated with a 0.5 M DBU solution in 
ACN for 5 min, washed with ACN, and dried. The resulting supports were then treated 
with concentrated aqueous ammonia-ethanol (3:1) for 1 h at 55 oC. After filtration of 
the solid supports,  the supports were washed with ethanol and the combined solutions 
were evaporated to dryness.  Sequences II and III were treated with 0.15 ml of 
triethylamine.tris(hydrofluoride) / triethylamine / N-methylpyrrolidone (4:3:6) for 2.5 h 
at 65 ºC to remove the TBDMS groups. The reactions were stopped by adding 0.3 ml of 
isopropoxytrimethylsilane and 0.75 ml of ether. The resulting mixtures were stirred and 
cooled at 4 ºC. A precipitate was formed which was then centrifuged at 7000 rpm for 5 
min at 4 ºC. The precipitates were washed with ether and centrifuged again. The 
residues were dissolved in water and the conjugates were purified by HPLC. Column: 
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Nucleosil 120-10 C18 (250x4 mm); 20 min linear gradient from 15%  to 80% B and 5 
min 80% B (DMT-on conditions, sequence I); 20 min linear gradient from 0%  to 50% 
B (DMT-off conditions, sequences II and III); flow rate 3 ml/min; solution A was 5% 
ACN in 0.1 M aqueous TEAA and B 70% ACN in 0.1 M aqueous TEAA. The purified 
products were analyzed by MALDI-TOF mass spectrometry. Sequence I [M] = 4161.0 
(expected M= 4165.3). Yield (0.5 mmol scale synthesis) was 12 OD units at 260 nm 
(120 nmol, 24%). Sequence II [M] = 3376.5 (expected M= 3377.2). Yield (0.5 mmol 
scale synthesis) was 1.7 OD units at 260 nm (25 nmol, 5%). Sequence III [M+Na+] = 
7785.7 (expected M= 7766.6). Yield (0.2 mmol scale synthesis) was 2.1 OD units at 260 
nm (10 nmol, 5%). The purified conjugates were judged to be homogeneous (purity 
>90%) by analytical HPLC and denaturing polyacrylamide gel electrophoresis. 
Analytical HPLC was performed using XBridgeTM OST C18 (Waters), 2.5 mm, 4.6 x 50 
mm column using a 10 min linear gradient from 0%  to 35% B, flow rate 1 ml/min; 
solution A was 5% ACN in 0.1 M aqueous TEAA and B 70% ACN in 0.1 M aqueous 
TEAA. 
Denaturing polyacrylamide gel electrophoreses were performed in a SE-600 Hoefer 
Scientific apparatus. The gels (8 M urea, 20%, acrylamide/ bisacrylamide ratio 19:1), 14 
x 16 x 0.1 cm in size were run for 5 h at 400 V. Three micrograms of RNA were loaded. 
The gel was stainned with Stains-all (Sigma). 
MALDI-TOF spectra were performed using a Perseptive Voyager DETMRP mass 
spectrometer, equipped with nitrogen laser at 337 nm using a 3ns pulse. The matrix 
used contained 2,4,6-trihydroxyacetophenone (THAP, 10 mg/ml in ACN/ water 1:1) 
and ammonium citrate (50 mg/ ml in water). 
 
Melting experiments.  
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Oligonucleotides (1 μM each)  were dissolved in 100 mM potassium acetate, 2 mM 
magnesium acatate, and 30 mM HEPES-KOH at pH 7.4. The solutions were heated to 
90 ºC, allowed to cool slowly to room temperature, and stored at 4ºC until UV was 
measured. UV absorption spectra and melting experiments (absorbance vs. temperature) 
were recorded in Teflon-stoppered 1-cm path length quartz cells using a 
spectrophotometer, with a temperature controller and a programmed temperature 
increase rate of 1 ºC/min. Melting curves were run in duplicate at 260 nm. In all cases 
the complexes displayed sharp, apparently two-state transitions. The data were analyzed 
by the denaturation curve-processing program. 
 
Cell culture, transfection and cellular assays.  
HeLa cells were cultured under standard conditions (37ºC, 5% CO2, Dulbecco’s 
Modified Eagle Medium, 10% fetal bovine serum, 2mM L-glutamine, supplemented 
with penicillin (100 U/ml) and streptomycin (100 mg/ml).  All experiments were 
conducted at 40-60% confluence. HeLa cells were transfected with 250 ng of murine 
expressing the TNF-a plasmid using lipofectin (Invitrogen), following the 
manufacturer’s instructions. One hour after transfection, m-TNF-a expressing HeLa 
cells were transfected with 50nM of siRNA (5’-GUGCCUAUGUCUCAGCCUC-dT-
dT-3’ / 5’ GAGGCUGAGACAUAGGCAC-dT-dT-3’, [31]) against TNF-a, using 
oligofectamine (Invitrogen). The TNF-a concentration was determined from cell culture 
supernatant by enzyme-linked immunoabsorbent assay kit (Bender MedSystems) 
following the manufacturer’s instructions.  
The unmodified siRNA duplex produced 87% inhibition of TNF-a compared with the 
scrambled siRNA sequence, cholesterol-modified siRNA produced 81% inhibition and 
nucleoplasmine-modified siRNA produced 89% inhibition (Fig. 3). 
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RESULTS AND DISCUSSION 
 
Synthesis of oligonucleotide-peptide conjugates  
Oligonucleotide-peptide conjugates carrying the nucleoplasmine nuclear localization 
sequence (AKKKKLDK) were synthesized following the stepwise approach.  
Polyethylenglycol-polystyrene (PEG-PS) was selected as solid support since it gave the 
best results for the coupling of amino acids and nucleoside phosphoramidites [20, 32, 
33]. Scheme 1 shows the outline of the synthesis of the oligonucleotide-peptide 
conjugates on the same support [20, 32, 33]. To avoid the use of strong acids in the 
presence of the oligonucleotide, the peptide part was first synthesized using the acid-
labile Boc group to protect the a-amino function. The protective groups of the side 
chain of the amino acids (Fmoc for Lys and Fm for Asp) and the linker of the first 
aminoacid to the support were base-labile so that they would be removed at the same 
time as the protective groups of the nucleobases. To this end, the 6-aminohexylsuccinyl 
(AmHex, [34]) was used. This linker yields the peptide with an aminohexylamide group 
at the C-terminal.  
Once the peptide had been synthesized, the p-nitrophenyl 6-(4,4'-
dimethoxytrityloxy)hexanoate spacer molecule [20] was added to connect the 
oligonucleotide. This molecule introduces an hydroxyl group protected by a DMT 
group at the N-terminal position of the peptide. After the addition of the linker, 
oligonucleotide synthesis was studied in a small 2’-O-methyl-RNA sequence (I: 5'-
uggauucgu-3’-p-O-(CH2)5CONH-NAKKKKLDKC-CONH-hexyl-OH) using a slightly 
modified synthesis cycle and 1H-tetrazole activation. The average coupling yield was 
around 99% per step. The last DMT group was not removed in order to facilitate the 
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purification of the conjugate by reversed phase HPLC (Fig. 1). The desired compound 
was purified in good yield and was characterized by mass spectrometry.  
We next studied the assembly of a short RNA sequence (II: 5' CUGAC-dT-ps-dT-3’-ps-
O-(CH2)5CONH-NAKKKKLDKC-CONH-hexyl-OH). This sequence contains 5 
ribonucleotides, 2 thymidine residues (dT) and 2 phosphorothioate (ps) linkages at the 
3’-end.  These are usual modifications in RNA interference studies. RNA monomers 
were protected with the t-butyldimethylsilyl (TBDMS) group. The same modified cycle 
for the synthesis of the 2’-O-methyl-RNA conjugate was used. In this case the coupling 
yield was slightly lower 97-98% as a result of steric hindrance of the TBDMS. The last 
DMT group was removed before deprotection because partial loss was detected during 
fluoride treament. For cleavage and deprotection, three consecutive treatments were 
applied: first a 0.5 M DBU solution in ACN; second, concentrate aqueous ammonia-
ethanol 3:1 at 55oC, and third, triethylamine tris(hydrofluoride) in N-methylpyrrolidone 
at 65ºC. HPLC purification gave a major product that had the mass expected. The yield 
obtained after purification (5%) was lower than that achieved in the synthesis of the 2’-
O-methyl-RNA conjugate (24%). This difference is attributed to the manipulation steps 
followed when removing the TBDMS groups. In order to eliminate the excess of 
fluoride, precipitation of the conjugate with ether is required and this may lower the 
recovery of the desired conjugate as a result of the small size of the oligomer (7mer).   
Finally, the 21mer sequence III) 5'- GUGCCUAUGUCUCAGCCUC-dT-dT-p-O-
(CH2)5CONH-NAKKKKLDKC-CONH-hexyl-OH was assembled using the same 
protocol described for sequence II. In this case the desired conjugate was isolated in a 
5% after HPLC purification (Fig. 2). The yield of the 21mer obtained after purification 
was the same as that of the 7mer but the former was three times longer, thereby 
indicating a more efficient recovery of the longer conjugate. The purified conjugate was 
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analyzed by HPLC and polyacrylamide gel electrophoresis and characterized by MADI-
TOF mass spectrometry. 
We examined the effect of the peptide on siRNA duplex stability. The thermal stability 
of the modified and unmodified duplexes was measured in 100 mM potassium acetate, 
2 mM magnesium acetate, and 30 mM HEPES-KOH at pH 7.4. The melting 
temperature (Tm) of the duplex containing nucleoplasmine was 83.8 ºC while the Tm of 
the unmodified duplex was 83.5 ºC. A slighty higher stabilization of the duplex has 
been described for this peptide on DNA duplexes [32] and it has been attributed to a 
possible interaction between lysine side chain and DNA phosphates. In the present 
study two unpaired thymidines separated the peptide from the DNA backbone, therefore 
it is reasonable to expect no differences between modified and unmodified duplexes. 
 
Inhibition of TNF-a. 
Oligonucleotide-peptide sequence III was annealed with equimolar amounts of the 
unmodified guide strand and the resulting duplex was used to inhibit the expression of 
the TNF-a gene. HeLa cells were transfected first with plasmid expressing murine 
TNF-a using lipofectin and 1 h later were co-transfected with the siRNA duplex (50 
nM) using oligofectamine. After 24 h the amount of TNF-a produced by the cells was 
analyzed by enzyme-linked immunoabsorbent assay (ELISA). Fig. 3 shows the amount 
of TNF-a produced after 24 h of transfection of 50nM siRNA unmodified duplexes. 
Modified and unmodified siRNA against TNF-a produced an 80-90% inhibition of the 
production of TNF-a compared with the scrambled control siRNA duplex.  These 
results indicate that the introduction of the peptide sequence at the 3’-end of the 
passenger strand of an RNA duplex does not affect the inhibitory properties of the 
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resulting siRNA duplex in HeLa cells. Further work is required to determine whether 
the presence of the peptide improves the delivery of the siRNA into cells.   
In conclusion, we have demonstrated that RNA carrying nucleosplasmine peptide can 
be synthesized using the stepwise approach. siRNA duplexes covalently linked to the 
nucleoplasmine peptide can be efficiently delivered to HeLa cells and these conjugates 
enter the RNAi pathway to silence gene expression as efficiently as unmodified and 3’-
cholesterol modified siRNA duplexes.    
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Scheme 1. Outline of the synthesis of oligonucleotide-3’-peptide conjugates. 
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Fig. 1.   HPLC profile of the product obtained after the synthesis of the nucleoplasmine-
oligo-2’-O-methyl(ribonucleotide) conjugate I (5'-uggauucgu-3’-p-O-(CH2)5CONH-
NAla-Lys-Lys-Lys-Lys-Leu-Asp-LysC-CONH-(CH2)6-OH) using DMT-on conditions. 
Product eluting at 12 min is the desired conjugate. Inset: analytical HPLC of the 
purified product (see experimental section). 
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Fig. 2.   HPLC profile of the product obtained after the synthesis of the nucleoplasmine-
oligoribonucleotide conjugate III (5'- GUGCCUAUGUCUCAGCCUC-dT-dT-p-O-
(CH2)5CONH-NAla-Lys-Lys-Lys-Lys-Leu-Asp-LysC-CONH-(CH2)6-OH) using DMT-
off conditions. Product eluting at 10 min is the desired conjugate. Inset: analytical 
HPLC of the purified product (see experimental section). 
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Fig. 3.   Potency in vivo of several chemically modified siRNAs against TNF-a. 
Amount of TNF-a produced after 24 h of transfection of 50nM siRNA unmodified 
duplex (Unmodified), 50 nM of the same siRNA duplex carrying a cholesterol molecule 
at the 3’-end of the passenger strand (Cholesterol), 50 nM of the same siRNA duplex 
carrying the nucleoplasmine peptide at the 3’-end of the passenger strand (sequence III, 
Nucleoplasmine) and 50 nM of a scrambled RNA duplex control sequence (Scr). Error 
bars represent the s.d of the mean. Statistical analysis was by ANOVA with Bonferroni 
post-test, one-tailed. ***or ### P<0.001 compared with scrambled siRNA. 
 
 
 
 
 
 
